Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Clinical Trial of NB-02 in Mild to Moderate Stages of Alzheimer's Disease

Next Previous
Trial Profile

A Phase IIa Clinical Trial of NB-02 in Mild to Moderate Stages of Alzheimer's Disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NB 02 (Primary)
  • Indications Alzheimer's disease
  • Focus First in man; Therapeutic Use

Most Recent Events

  • 11 Aug 2020 According to a NeuroBo Pharmaceuticals media release, the company intends to postpone the first human clinical trials for NB-02 until global health and macroeconomic conditions improve, with a view toward commencing clinical trial activity in the first half of 2021, subject to improvement of the constraints imposed by the COVID-19 pandemic. The company is also considering engaging with a strategic partner to assist with clinical trials for NB-02.
  • 20 May 2020 According to a NeuroBo Pharmaceuticals media release, the company is planning to submit an Investigational New Drug application to the U.S. Food and Drug Administration to initiate this study in the first quarter of next year.
  • 10 Jan 2020 According to a NeuroBo Pharmaceuticals media release, the company is in the process of designing this first-in-human trial for NB-02 for Alzheimer's-disease.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top